A Phase 1, Randomized, Multi-center, Double-blind, Sponsor Open, Placebo-controlled, Single And Multiple Dose-escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2018
At a glance
- Drugs PF-06835375 (Primary) ; PF-06835375 (Primary)
- Indications Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Pfizer
- 05 Jun 2018 Planned End Date changed from 22 Nov 2022 to 22 Nov 2021.
- 05 Jun 2018 Planned primary completion date changed from 22 Nov 2022 to 22 Nov 2021.
- 17 May 2018 Planned End Date changed from 15 Nov 2021 to 22 Nov 2022.